In 2025, Zhenqi Liu and team from the University of Virginia reviewed studies on GLP-1 drugs like Ozempic, focusing on their impact on cardiorespiratory fitness (CRF), a key predictor of heart health and longevity. While these drugs drive significant weight loss, they also reduce fat-free mass (25-40% of total weight lost), including vital muscle, raising concerns about long-term health.